Discontinued — last reported Q1 '26
Business Segments · Proceeds from legal settlements
U.S. Pharmaceutical — Proceeds from legal settlements
McKesson U.S. Pharmaceutical — Proceeds from legal settlements decreased by 96.9% to $8M in Q2 2025 compared to the prior quarter. Year-over-year, this metric declined by 91.1%, from $90M to $8M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryOther
SignalHigher is better
VolatilityVolatile
First reportedQ1 2019
Last reportedQ1 2026Aug 6, 2025
Rolls up toProceeds from legal settlements
How to read this metric
Higher proceeds indicate successful legal outcomes but do not reflect sustainable operational growth.
Detailed definition
Reflects cash or value received by the U.S. Pharmaceutical segment resulting from the resolution of legal disputes or li...
Peer comparison
Common in highly regulated industries like pharmaceutical distribution where litigation is frequent.
Metric ID:
mck_segment_u_s_pharmaceutical_proceeds_from_legal_settlementsHistorical Data
11 periods
| Q2 '22 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $34M | $129M | $118M | $79M | $23M | $24M | $90M | $63M | $31M | $260M | $8M |
| QoQ Change | — | +279.4% | -8.5% | -33.1% | -70.9% | +4.3% | +275.0% | -30.0% | -50.8% | +738.7% | -96.9% |
| YoY Change | — | — | — | — | -82.2% | — | -23.7% | -20.3% | +34.8% | +983.3% | -91.1% |
Range$8M – $260M
CAGR-43.9%
Avg YoY Growth+133.5%
Median YoY Growth-22.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's u.s. pharmaceutical — proceeds from legal settlements?
- McKesson (MCK) reported u.s. pharmaceutical — proceeds from legal settlements of $8M in Q2 2025.
- How has McKesson's u.s. pharmaceutical — proceeds from legal settlements changed year-over-year?
- McKesson's u.s. pharmaceutical — proceeds from legal settlements decreased by 91.1% year-over-year, from $90M to $8M.
- What does u.s. pharmaceutical — proceeds from legal settlements mean?
- Cash inflows received by the segment from legal settlements or litigation resolutions.